There is a very unpleasant pattern appearing here which shows Steve O’Hara, the boss of Optibiotix (OPTI), where I remain a loyal shareholder, in a very poor light. This was flagged up by Lemming Investor at the weekend. Lemming and I have both supported Optibiotix and O’Hara in the past but no more.
As each day goes by the case for replacing almost all of the board at Optibiotix (OPTI) grows louder and louder. It is incompetent, mendacious and overpaid. CEO Steve O’Hara remains adamant that they are all doing a great job but here is another shocker. I have written to my good pals at the Financial Reporting Council about new “crimes” picked up by reader M
I have written to Liam “the Toke” Murray at Nomad Cairn and, in case, he is dozing on a mushroom, cc’d in AIM Regulation regarding the 23 May £500,000 raised by Optibiotix (OPTI) with what it termed a specialist “institutional investor” and what lyin’ Steve O’Hara subsequently stated was a “strategic investor,” Alumni Capital. A new RNS is needed.
On Friday 23 May Optibiotix (OPTI) announced a placing with a US “specialist” investor taking £500,000 of shares at 14p. It did not name that investor but the implication was that this was a kosher long term fundamentals based investor. Even yesterday Steve O'Hara was briefing that it was a "strategic investor." Today it has updated its Rule 26 page and the ghastly truth is starting to slip out.
It is the responsibility of the “institutional investor” who Steve O’Hara claims put £500,000 unto Optibiotix (OPTI) in last Friday’s discounted 14p placing, to serve up a TR1. It has not because it no longer owns more than 3% of the equity. Who says so? Optibiotix!
I accept that it is the responsibility of the “investor” who Steve O’Hara claims put £500,000 unto Optibiotix (OPTI) in last Friday’s discounted 14p placing, to serve up a Tr1. But as the trade now happened more than a week ago, O’Hara could chase the matter or could simply name the investor. He will not. Just as he now refuses to return calls or emails from me. It is not as if he wants to move forward amicably and behind closed doors.
Over on the LSE Asylum on the Optibiotix (OPTI) thread I am being called a rank amateur and worse. Obviously one must defer to folks with the collective IQ of a park bench.
If Liam “the Toke” Murray at Nomad Cairn was not either useless or stoned he would have, by now, forced someone at Optibiotix (OPTI) to fall, on his sword for fabricating an RNS quote from a then unconscious CEO on October 10 last year, a clear breach of AIM Rule 10. And with that failing we now turn to the missing TR1 which may show Optibiotix lied in an RNS.
On Friday morning, Optibiotix (OPTI), whose liar of a CEO had said that it was funded through to profitability later this year, announced a discounted placing at 14p with warrants at 21p. The lying CEO, Steve O’Hara, insisted that £500,000 of that cash came from a specialist “institutional investor with previous experience of investing in companies with weight management products who became aware of OptiBiotix's recent launches of SlimBiome products in the USA.” I bet my entire Cheryl Cole poster collection that this was bollocks.
Lemming junior appears not to like me very much so it will pain him greatly that I think his latest article on Optibiotix (OPTI) is bang on the money except in suggesting that I have made “numerous” calls to Lemming senior. The company serves up great news today and its shares don’t move. Surely even Steve O’Hara realizes the reasons why now?
Someone at Optibiotix (OPTI) may have breached AIM Rule 10 and possibly committed fraud in pushing out a grotesquely misleading statement. Is it chairman Neil Davidson, partner of the ghastly ex Tory MP Anna Soubry. I have written to the regulators, ccing in hapless Nomad Liam Murray at Cairn and broker Peterhouse urging an investigation. Or maybe they will just try to sweep this under the carpet because it would not do to upset the establishment would it?
I thought Optibiotix (OPTI) was in a closed period so Steve O’Hara should not be commenting on trading. He certainly releases price sensitive information in the podcast he has recorded below about new orders in the USA, India and Oz. This should be an RNS. It is positive from a trading perspective but this is another PR feck up which screams out the need for boardroom change. And there is worse.
Steve O'Hara does not seem to want to take my call. So I have written to the Optibiotix (OPTI) CEO, ccing in his advisors. If you area shareholder who wants more transparency, cost control and regime change, please pledge your support HERE. I write:.
The Optibiotix (OPTI) CEO has recorded a 12 minute monologue. Listen and I defy anyone not to say why this does not leave the shares hugely cheap at 18.5p, a market cap of c£18 million. This really is a cue to FYB. Here are the key takeaways:
OptiBiotix Health (OPTI) has announced a “first order from a leading weight management brand in the United States of America” and that “further information on the partner and brand will be announced on launch which the company anticipates will be in H1 2025”. So how encouraging is this latest order from an up to 17.5p share price, £17.1 million OptiBiotix market capitalisation?
Hitherto a seller of Optibiotix (OPTI) and a critic of it in many ways, it seems that one sinner, my good pal the Lemming, has repented. He has posted on a Bulletin Board:
